Clinical Study

A Multicenter Phase 1/2B Study Of The Bruton’S Tyrosine Kinase Inhibitor, Ibrutinib (Pci-32765), In Combination With Carfilzomib (Kyprolis™) In Subjects With Relapsed Or Relapsed And Refractory Multiple Myeloma

Posted Date: Aug 2, 2017

  • Investigator: Saulius Girnius
  • Co-Investigator: Bridget Kinne
  • Specialties: Hematology/Oncology, Oncology, Cancer
  • Type of Study: Drug

The study drug Ibrutinib (PCI-32765 or IMBRUVICA®) is a type of drug called a kinase inhibitor. Kinases are proteins that help cells live and grow. The specific kinase blocked by ibrutinib is believed to help blood cancer cells live and grow. By inhibi


To Be Eligible For This Study, Patients Must Have Multiple Myeloma


Pcyc-1119-Ca, Phase I, Cancer, Multiple Myeloma, Hematology

For More Information:

Uc Cancer Institute

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.